Nobilis Health Corp.
HLTH
HLTH was delisted on the 3rd of September, 2019.
3 hedge funds and large institutions have $57K invested in Nobilis Health Corp. in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 18 closing their positions.
85% less funds holding
Funds holding: 20 → 3 (-17)
88% less capital invested
Capital invested by funds: $482K → $57K (-$425K)
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$2.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$228K |
| 2 |
AWW
Alan W. Weber
|
-$83K |
| 3 |
VF
Virtu Financial
New York
|
-$61K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7K |
HLTH Hedge Fund Activity: Q3 2019 in Review
3 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Nobilis Health Corp. (HLTH) for Q3 2019, worth a combined $57K — down 88% from $482K a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of HLTH and 1 opened new positions — a net loss of 17 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $2.68K. The largest seller was Vanguard Group, exiting entirely with an estimated $228K sold.
- 3 institutional investors held Nobilis Health Corp. (HLTH) as of Q3 2019, down from 20 in Q2 2019.
- Funds reported $57K of Nobilis Health Corp. stock for Q3 2019, down 88% quarter-over-quarter.
- 1 fund opened new Nobilis Health Corp. positions in Q3 2019 and 18 closed out, a net change of -17 holders.
- The largest Nobilis Health Corp. buyer in Q3 2019 was HRT Financial, an estimated $2.68K added.
- The largest Nobilis Health Corp. seller in Q3 2019 was Vanguard Group, an estimated $228K sold.
Based on aggregated 13F filings for Q3 2019.